.25 of semaglutide Obesity Semalix 0.25 mg/0.5 mg Pre-filled

This isn't a complete list - review full safety information with your prescriber before starting treatment

04/05/24 Abecma (idecabtagene vicleucel) Expanded indication April 5, 2024 - Bristol Myers Squibb and 2seventy bio announced the FDA approval of Abecma (idecabtagene vicleucel), for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody

Patients should contact their healthcare provider promptly if they experience severe abdominal pain, persistent nausea and vomiting, signs of pancreatitis, or any concerning symptoms

53 In a phase 2 randomized, double-blind trial, weekly injections of retatrutide (1 mg12 mg) led to weight reductions of 7.217.5% at 24 weeks and 8.724.2% at 48 weeks in individuals with obesity or pre-obesity (without diabetes), compared to 1.6% and 2.1% with placebo, respectively, showing no plateau in this period (Table 2)

This can lead to dehydration and electrolyte imbalances